ESTRO 2024 - Abstract Book

S1105

Clinical - Gynaecology

ESTRO 2024

Conclusion:

In selected patients with oligometastatic pelvic relapse of gynaecological cancer following previous pelvic radiotherapy, SBRT reirradiation is an effective and safe treatment modality. SBRT reirradiation can provide durable local control and delay time to systemic therapy by >12 months. Our outcomes are comparable to other smaller published case series 1,2 .

Keywords: SBRT, Reirradiation, Gynaecology

References:

1. Ling DC, Vargo JA, Burton SA, Heron DE, Beriwal S. Salvage Curative-Intent Reirradiation Stereotactic Body Radiation Therapy for Isolated Pelvic and/or Paraortic Recurrences of Gynecologic Malignancies. Pract Radiat Oncol. 2019;9(6):418-425. doi:10.1016/j.prro.2019.05.012 2. Park HJ, Chang AR, Seo Y, et al. Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11). Anticancer Res. 2015;35(9):5103-5110. 3. Seo Y, Kim MS, Yoo HJ, et al. Salvage stereotactic body radiotherapy for locally recurrent uterine cervix cancer at the pelvic sidewall: Feasibility and complication. Asia Pac J Clin Oncol. 2016;12(2):e280-288. doi:10.1111/ajco.12185

4. Slevin F, Aitken K, Alongi F, et al. An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation. Radiother Oncol. 2021;164:104-114. doi:10.1016/j.radonc.2021.09.010

5. Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008;18(4):215-222. doi:10.1016/j.semradonc.2008.04.001

2860

Digital Poster

Intensity modulated radiation therapy boost in cervical cancer in the absence of brachytherapy